08:00 , Feb 20, 2006 |  BioCentury  |  Strategy

A near death experience

Four years ago, with barely E1 million in the bank, Pharming Group N.V. was forced into receivership, having bitten off more than it could chew trying to develop alpha glucosidase to treat Pompe's disease in...
08:00 , Dec 6, 2004 |  BC Week In Review  |  Company News

Angiotech management update

Angiotech Pharmaceuticals Inc. (TSE:ANP; ANPI), Vancouver, B.C.   Business: Cardiovascular   Departed: George Daniloff as SVP of R&D and general manager of ANPI subsidiary Cohesion Technologies Inc.  ...
07:00 , Oct 25, 2004 |  BC Week In Review  |  Company News

Angiotech drug delivery news

ANP said it is planning to disclose on its Nov. 3 earnings call that it has started to consolidate its facilities, a task that will be spread out over the next year. The company said...
07:00 , Oct 15, 2004 |  BC Extra  |  Company News

Angiotech consolidating

Angiotech (TSE:ANP; ANPI) is planning to disclose on its Nov. 3 earnings call that it has started to consolidate its far-flung facilities, a task that will be spread out over the next year. According to...
07:00 , Jun 28, 2004 |  BC Week In Review  |  Company News

Angiotech, NeuColl deal

ANP will acquire the portion of collagen-based products company NeuColl that it does not already own for $13 million in cash. ANP obtained an equity interest in NeuColl through its 2003 acquisition of Cohesion Technologies...
07:00 , Jul 21, 2003 |  BC Week In Review  |  Clinical News

Adhibit: Pivotal trial; marketed to reduce post-surgical adhesion formation in pediatric patients undergoing cardiac surgery

ANP subsidiary Cohesion Technologies Inc. (Palo Alto, Calif.) began enrollment of 60 patients in an open-label pivotal trial in Germany. Patients undergoing laparoscopic removal of uterine fibroids will receive Adhibit sprayed on the surgical site....
08:00 , Mar 3, 2003 |  BC Week In Review  |  Company News

Angiotech, Baxter Healthcare Corp. deal

BAX licensed worldwide rights, excluding Japan and certain other regions, to market and distribute ANP's CoSeal surgical sealant and Adhibit surgical anti-adhesive product. BAX will immediately begin marketing CoSeal. ANP will receive an upfront payment...
08:00 , Feb 25, 2003 |  BC Extra  |  Company News

Angiotech, Baxter surgical sealant deal

BAX licensed worldwide rights, excluding Japan and certain other regions, to market and distribute Angiotech's CoSeal surgical sealant and Adhibit surgical anti-adhesive product. BAX will immediately begin marketing CoSeal. Angiotech (TSE:ANP; ANPI) expects to receive...
08:00 , Feb 24, 2003 |  BC Week In Review  |  Clinical News

CoSeal surgical sealant: Approved as a vascular sealant

ANP began an open-label European study in 30 patients undergoing a lung resection. CoSeal will be placed over sutures or staples to prevent air leaks. The company said the study could be used to expand...
08:00 , Feb 17, 2003 |  BC Week In Review  |  Company News

Angiotech management update

Angiotech Pharmaceuticals Inc. (TSE:ANP; ANPI), Vancouver, B.C.   Business: Cardiovascular   Hired: George Daniloff as general manager and VP of R&D, formerly VP of R&D at Cohesion Technologies Inc. (CSON), which ANP is acquiring; and...